Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27476458 | 0.76 | HSP90AA1 (0.32) | — | |
| SCHEMBL6142174 | 0.76 | LMNA (0.39) | PARP1VCPPTGES | |
| SCHEMBL6985345 | 0.73 | CBFB (0.40) | PARP1RPS6KA3 | |
| SCHEMBL6142180 | 0.73 | CYP3A4 (0.48) | PARP1HTT | |
| Hydrochloric Acid SCHEMBL11784418 | 0.72 | EGLN1 (0.40) | PARP1RPS6KA3 | |
| SCHEMBL6993967 | 0.71 | VSIR (0.36) | PARP1RPS6KA3HRH4 | |
| SCHEMBL13594653 | 0.70 | ADRB2 (0.52) | PARP1ADRB2HTTDHODH | |
| SCHEMBL6509697 | 0.70 | ADRB2 (0.58) | PARP1ADRB2RPS6KA3HTTDHODH | |
| SCHEMBL6142607 | 0.70 | RPS6KA3 (0.60) | PARP1ADRB2RPS6KA3HTTDHODH | |
| SCHEMBL353026 | 0.69 | CBFB (0.51) | PARP1ADRB2RPS6KA3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944604-B1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2005-01-12 | — | — | EP | claimed |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-09-12 | — | — | US | claimed |
| US-6225331-B1 | FOR THERAPY AND PROPHYLAXIS NASAL CONGESTION, OTITIS MEDIA, AND SINUSITIS, TREATING COUGH, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA, BENIGN PROSTATIC HYPERTROPHY, CARDIOVASCULAR DISORDERS, GLAUCOMA, HYPEREMIA, CONJUNCTIVITIS | THE PROCTER & GAMBLE COMPANY | 2001-05-01 | — | — | US | claimed |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2001-04-19 | — | — | US | claimed |
| EP-0944604-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023596-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0944604-B1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-09-12 | — | — | US | disclosed |
| US-6391878-B2 | COMPOUNDS SUCH AS (4,7-DIMETHYLBENZIMIDAZOL-5-YL)GUANIDINE; TREATING NASAL CONGESTION, OTITIS MEDIA, ASTHMA, PAIN, MIGRAINE, GASTROINTESTINAL DISORDER, ULCER | THE PROCTER & GAMBLE COMPANY | 2002-05-21 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| US-6225331-B1 | FOR THERAPY AND PROPHYLAXIS NASAL CONGESTION, OTITIS MEDIA, AND SINUSITIS, TREATING COUGH, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA, BENIGN PROSTATIC HYPERTROPHY, CARDIOVASCULAR DISORDERS, GLAUCOMA, HYPEREMIA, CONJUNCTIVITIS | THE PROCTER & GAMBLE COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2001-04-19 | — | — | US | disclosed |
| EP-0944604-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023596-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | PARP1 3971/4885ADRB2 1/4885RPS6KA3 3337/4885 |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | ADRB2, ADRA2C, ADRA2B | PARP1 3103/4885ADRB2 1/4885RPS6KA3 3809/4885 |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | ADRB2, ADRA2C, ADRA2A | PARP1 2870/4885ADRB2 1/4885RPS6KA3 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.